Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.

Astria Therapeutics, Inc.

Astria Therapeutics develops therapies for patients and families affected by allergic and immunologic diseases. Self-described as patient-focused, the company aims to bring life-changing treatments.

NASDAQ:ATXS

Astria Therapeutics

Last Close

12.50

25/09 14:39

Market Cap

572.19M

Beta: 0.92

Volume Today

314.69K

Avg: 227.03K

PE Ratio

−7.69

PFCF: −15.76

locale

market

industry

website

ipo date

Earnings

Earnings per Share (Estimate*)

Revenue (Estimate*)

Metrics